University of California San Francisco

Norah Terrault - 144
Norah
Terrault
MD, MPH

Professor of Clinical Medicine & Surgery
Departments of Medicine & Surgery
Director of Viral Hepatitis Research in Liver Transplantation

Address

513 Parnassus Avenue, MSB, #357
San Francisco, CA 94143
United States

Email: [email protected]
Phone: 415-476-2227
Fax: 415-476-0659

    Biography

    Dr. Norah Terrault is a hepatologist or liver specialist who is recognized internationally for the treatment of viral hepatitis and liver transplantation. Her research includes the study of viral hepatitis and its progression and treatment, especially in liver transplant patients. Her research includes several clinical trials related to preventing and treating chronic hepatitis C and B. Her studies in this area have been presented to the American Association for the Study of Liver Diseases, the leading organization for research in liver disease.

    Terrault completed medical training at the University of Alberta and specialty medical training in Internal Medicine and Gastroenterology at the University of Toronto, both in Canada. Her post-doctoral fellowship in hepatology and viral hepatitis was completed at the University of California, San Francisco while earning a concurrent master's degree in public health from the University of California at Berkeley. She joined the medical staff at UCSF Medical Center in 1997.

    Education

    Institution Degree Dept or School End Date
    University of California, San Francisco Post-Doc Fellow/Scholar Medicine 1995
    University of Alberta M.D. School of Medicine 1987
    University of California, San Francisco Residency
    University of California, San Francisco Clinical Fellowship Gastroenterology

    Board Certifications

    American Board of Internal Medicine, Internal Medicine

    American Board of Internal Medicine, Gastroenterology

    Clinical Expertise

    Alcoholic Liver Disease
    Autoimmune Hepatitis
    Benign Liver Tumors
    Cirrhosis
    Fulminant Hepatic Failure
    Hepatitis B
    Hepatitis C
    Hepatocellular Carcinoma (Liver Cancer)
    Live Donor Liver Transplantation
    Liver Transplantation
    Nonalcoholic Fatty Liver Disease
    Pancreas Transplantation
    Primary Biliary Cirrhosis
    Primary Sclerosing Cholangitis

    Clinical Trials

    1. Related Conditions: Hepatitis C, Viruses, Hepatocellular Cancer, Liver Cancer, Hepatitis, Cirrhosis, Liver Transplant, Hepatitis A| Start Date: | End Date:
    2. Related Conditions: Hepatitis B, Liver Disease, Liver Transplant, Hepatitis A, Hepatitis| Start Date: | End Date:

    Program Affiliations

    UCSF Liver Center

    In the News

    December, 20, 2014 | UCSF Transplant Surgery

    Grants and Funding

    • USC Cirrhosis Clinical Center | NIH | 2021-09-22 - 2026-08-31 | Role: Principal Investigator
    • Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) | NIH | 2002-06-15 - 2024-06-30 | Role: Principal Investigator
    • Hepatitis B Research Network (HBRN): Natural History and Treatment Studies | NIH | 2008-09-30 - 2021-05-31 | Role: Principal Investigator
    • Bay Area Hepatitis C Cooperative Research Center | NIH | 2010-06-15 - 2016-05-31 | Role: Co-Investigator
    • General Clinical Research Center | NIH | 1974-12-01 - 2009-03-31 | Role: Co-Investigator
    • Resistance to Antiviral Therapy in Chronic Hepatitis C | NIH | 2001-08-01 - 2007-04-30 | Role: Principal Investigator

    Research Narrative

    My research focuses on the natural history and treatment of hepatitis C virus (HCV) and hepatitis B virus (HBV), particularly in special populations, including those undergoing liver transplantation. Work in progress addresses the natural history of post-transplant disease and specific therapies to prevent infection or modify HCV and HBV disease progression and loss of grafts from recurrent disease.

    Our virological analyses are focused on characterization of viral mutations that occur in liver transplant recipients receiving antiviral therapies and assessment of the effect of these variant viruses on the natural history and severity of disease post-transplantation. Knowledge of these factors may allow improved organ allocation by identifying subsets of patients with HCV recurrence in liver grafts who would be favorable or unfavorable candidates for retransplantation. 

    Research Interests

    Liver Injury and Repair

    Hepatitis B virus (HBV)

    Hepatitis C virus (HCV)

    Publications

    MOST RECENT PUBLICATIONS FROM A TOTAL OF 414
    1. The University of Southern California psychosocial checklist: A novel tool to remotely screen transplant candidates with alcohol-associated liver disease prior to hospital transfer.
      Edwards B, Ramirez S, Pappas J, Dodge JL, Han H, Kahn J, Ahearn A, Terrault NA, Lee BP| | PubMed
    2. Safety of acamprosate for alcohol use disorder after liver transplant: A pilot randomized controlled trial.
      Ayyala-Somayajula D, Bottyan T, Shaikh S, Lee BP, Cho SH, Dodge JL, Terrault NA, Han H| | PubMed
    3. Liver stiffness progression in biopsy-proven metabolic dysfunction-associated steatotic disease among people with diabetes versus people without diabetes: A prospective multicenter study.
      Huang DQ, Wilson LA, Behling C, Amangurbanova M, Kleiner DE, Kowdley KV, Dasarathy S, Terrault NA, Diehl AM, Chalasani N, Neuschwander-Tetri BA, Sanyal AJ, Tonascia J, Loomba R, NASH Clinical Research Network| | PubMed
    4. Use of HBsAg-positive donors in liver transplantation: An ILTS-EASL-AASLD multisociety survey.
      Vinaixa C, DiMaira T, Russo FP, Goldberg D, Mazzola A, Walabh P, Price J, Sagal S, Kirchner V, Shaker T, Krag A, Pruett T, Coilly A, Terrault N, Berenguer M| | PubMed
    5. The Survival Benefit of Reabstinence After Harmful Alcohol Use Following Early Liver Transplant for Severe Alcohol-Associated Hepatitis: A Multicenter ACCELERATE Study.
      Dukewich M, Dodge JL, Lucey MR, Rice JP, Shetty K, Jakhete N, Im GY, Weinberg EM, Hsu C, Smith C, Ghobrial RM, Therapondos G, Shoreibah M, Aryan M, Eswaran S, Fix OK, Maddur H, Terrault N, Lee BP| | PubMed
    6. The impact of surging transplantation of alcohol-associated liver disease on transplantation for HCC and other indications.
      Ayyala-Somayajula D, Dodge JL, Zhou K, Terrault NA, Yuan L| | PubMed
    7. Neighborhood-level Social Determinants of Health and Waitlist Mortality for Liver Transplantation: The Liver Outcomes and Equity Index.
      Zhou K, Lit A, Kuo LS, Thompson LK, Dodge JL, Mehta N, Terrault NA, Ha NB, Cockburn MG| | PubMed
    8. Liver transplantation for alcohol-associated liver disease.
      Simonetto DA, Winder GS, Connor AA, Terrault NA| | PubMed
    9. Reply: The exact predictive value of HBcrAg and HBV RNA in serological status and disease activity in CHB.
      Ghany MG, King WC, Hinerman AS, Lok ASF, Lisker-Melman M, Chung RT, Terrault N, Janssen HLA, Khalili M, Lee WM, Lau DTY, Cloherty GA, Sterling RK| | PubMed
    10. Designing clinical trials to address alcohol use and alcohol-associated liver disease: an expert panel Consensus Statement.
      Lee BP, Witkiewitz K, Mellinger J, Anania FA, Bataller R, Cotter TG, Curtis B, Dasarathy S, DeMartini KS, Diamond I, Diazgranados N, DiMartini AF, Falk DE, Fernandez AC, German MN, Kamath PS, Kidwell KM, Leggio L, Litten R, Louvet A, Lucey MR, McCaul ME, Sanyal AJ, Singal AK, Sussman NL, Terrault NA, Thursz MR, Verna EC, Radaeva S, Nagy LE, Mitchell MC| | PubMed